Works matching AU Camidge, D. Ross

Results: 66
    1
    2

    First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors.

    Published in:
    Oncologist, 2021, v. 26, n. 11, p. 925, doi. 10.1002/onco.13911
    By:
    • Do, Khanh T.;
    • Chow, Laura Quan Man;
    • Reckamp, Karen;
    • Sanborn, Rachel E.;
    • Burris, Howard;
    • Robert, Francisco;
    • Camidge, D. Ross;
    • Steuer, Conor E.;
    • Strickler, John H.;
    • Weise, Amy;
    • Specht, Jennifer M.;
    • Gutierrez, Martin;
    • Haughney, Peter;
    • Hengel, Shawna;
    • Derleth, Christina Louise;
    • Yap, Timothy A.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10

    Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.

    Published in:
    Neuro-Oncology, 2022, v. 24, p. 1613, doi. 10.1093/neuonc/noac118
    By:
    • Aizer, Ayal A;
    • Lamba, Nayan;
    • Ahluwalia, Manmeet S;
    • Aldape, Kenneth;
    • Boire, Adrienne;
    • Brastianos, Priscilla K;
    • Brown, Paul D;
    • Camidge, D Ross;
    • Chiang, Veronica L;
    • Davies, Michael A;
    • Hu, Leland S;
    • Huang, Raymond Y;
    • Kaufmann, Timothy;
    • Kumthekar, Priya;
    • Lam, Keng;
    • Lee, Eudocia Q;
    • Lin, Nancy U;
    • Mehta, Minesh;
    • Parsons, Michael;
    • Reardon, David A
    Publication type:
    Article
    11

    Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L.

    Published in:
    Current Medical Research & Opinion, 2022, v. 38, n. 9, p. 1587, doi. 10.1080/03007995.2022.2100653
    By:
    • Reckamp, Karen L.;
    • Lin, Huamao M.;
    • Cranmer, Holly;
    • Wu, Yanyu;
    • Zhang, Pingkuan;
    • Kay, Stephen;
    • Walton, Laura J.;
    • Shen, Junwu;
    • Popat, Sanjay;
    • Camidge, D. Ross
    Publication type:
    Article
    12

    Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs.

    Published in:
    JAMA: Journal of the American Medical Association, 2014, v. 311, n. 19, p. 1998, doi. 10.1001/jama.2014.3741
    By:
    • Kris, Mark G.;
    • Johnson, Bruce E.;
    • Berry, Lynne D.;
    • Kwiatkowski, David J.;
    • Iafrate, A. John;
    • Wistuba, Ignacio I.;
    • Varella-Garcia, Marileila;
    • Franklin, Wilbur A.;
    • Aronson, Samuel L.;
    • Pei-Fang Su;
    • Yu Shyr;
    • Camidge, D. Ross;
    • Sequist, Lecia V.;
    • Glisson, Bonnie S.;
    • Khuri, Fadlo R.;
    • Garon, Edward B.;
    • Pao, William;
    • Rudin, Charles;
    • Schiller, Joan;
    • Haura, Eric B.
    Publication type:
    Article
    13
    14
    15
    16
    17
    18

    A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.

    Published in:
    Clinical Lung Cancer, 2023, v. 24, n. 3, p. 228, doi. 10.1016/j.cllc.2023.01.009
    By:
    • Iams, Wade T.;
    • Balbach, Meridith L.;
    • Phillips, Sharon;
    • Sacher, Adrian;
    • Bestvina, Christine;
    • Velcheti, Vamsidhar;
    • Xiao Wang;
    • Marmarelis, Melina E.;
    • Sethakorn, Nan;
    • Leal, Ticiana;
    • Sackstein, Paul E.;
    • Chul Kim;
    • Robinson, Md Andrew;
    • Mehta, Kathan;
    • Hsu, Robert;
    • Nieva, Jorge;
    • Patil, Tejas;
    • Camidge, D. Ross
    Publication type:
    Article
    19
    20
    21

    A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

    Published in:
    Clinical Lung Cancer, 2022, v. 23, n. 4, p. 300, doi. 10.1016/j.cllc.2022.03.003
    By:
    • Camidge, D. Ross;
    • Moran, Teresa;
    • Demedts, Ingel;
    • Grosch, Heidrun;
    • Mileham, Kathryn;
    • Molina, Julian;
    • Juan-Vidal, Oscar;
    • Bepler, Gerold;
    • Goldman, Jonathan W.;
    • Keunchil Park;
    • Wallin, Johan;
    • Wijayawardana, Sameera R.;
    • Xuejing Aimee Wang;
    • Wacheck, Volker;
    • Smit, Egbert
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non--Small-Cell Lung Cancer.

    Published in:
    Clinical Lung Cancer, 2014, v. 15, n. 3, p. 188, doi. 10.1016/j.cllc.2013.12.005
    By:
    • von Pawel, Joachim;
    • Harvey, Jimmie H.;
    • Spigel, David R.;
    • Dediu, Mircea;
    • Reck, Martin;
    • Cebotaru, Cristina L.;
    • Humphreys, Robin C.;
    • Gribbin, Matthew J.;
    • Fox, Norma Lynn;
    • Camidge, D. Ross
    Publication type:
    Article
    36
    37
    38
    39

    Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

    Published in:
    Nature Communications, 2016, v. 7, n. 11, p. 13513, doi. 10.1038/ncomms13513
    By:
    • Chabon, Jacob J.;
    • Simmons, Andrew D.;
    • Lovejoy, Alexander F.;
    • Esfahani, Mohammad S.;
    • Newman, Aaron M.;
    • Haringsma, Henry J.;
    • Kurtz, David M.;
    • Stehr, Henning;
    • Scherer, Florian;
    • Karlovich, Chris A.;
    • Harding, Thomas C.;
    • Durkin, Kathleen A.;
    • Otterson, Gregory A.;
    • Thomas Purcell, W.;
    • Ross Camidge, D.;
    • Goldman, Jonathan W.;
    • Sequist, Lecia V.;
    • Piotrowska, Zofia;
    • Wakelee, Heather A.;
    • Neal, Joel W.
    Publication type:
    Article
    40

    Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

    Published in:
    Nature Communications, 2016, v. 7, n. 6, p. 11815, doi. 10.1038/ncomms11815
    By:
    • Chabon, Jacob J.;
    • Simmons, Andrew D.;
    • Lovejoy, Alexander F.;
    • Esfahani, Mohammad S.;
    • Newman, Aaron M.;
    • Haringsma, Henry J.;
    • Kurtz, David M.;
    • Stehr, Henning;
    • Scherer, Florian;
    • Karlovich, Chris A.;
    • Harding, Thomas C.;
    • Durkin, Kathleen A.;
    • Otterson, Gregory A.;
    • Purcell, W. Thomas;
    • Camidge, D. Ross;
    • Goldman, Jonathan W.;
    • Sequist, Lecia V.;
    • Piotrowska, Zofia;
    • Wakelee, Heather A.;
    • Neal, Joel W.
    Publication type:
    Article
    41
    42
    43

    Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

    Published in:
    Cancer (0008543X), 2015, v. 121, n. 6, p. 883, doi. 10.1002/cncr.29132
    By:
    • Doebele, Robert C.;
    • Spigel, David;
    • Tehfe, Mustapha;
    • Thomas, Sachdev;
    • Reck, Martin;
    • Verma, Sunil;
    • Eakle, Janice;
    • Bustin, Frederique;
    • Goldschmidt, Jerome;
    • Cao, Dachuang;
    • Alexandris, Ekaterine;
    • Yurasov, Sergey;
    • Camidge, D. Ross;
    • Bonomi, Philip
    Publication type:
    Article
    44

    Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

    Published in:
    Cancer (0008543X), 2015, v. 121, n. 3, p. 448, doi. 10.1002/cncr.29042
    By:
    • Villaruz, Liza C.;
    • Socinski, Mark A.;
    • Abberbock, Shira;
    • Berry, Lynne D.;
    • Johnson, Bruce E.;
    • Kwiatkowski, David J.;
    • Iafrate, A. John;
    • Varella‐Garcia, Marileila;
    • Franklin, Wilbur A.;
    • Camidge, D. Ross;
    • Sequist, Lecia V.;
    • Haura, Eric B.;
    • Ladanyi, Mark;
    • Kurland, Brenda F.;
    • Kugler, Kelly;
    • Minna, John D.;
    • Bunn, Paul A.;
    • Kris, Mark G.
    Publication type:
    Article
    45

    A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.

    Published in:
    Cancer (0008543X), 2014, v. 120, n. 8, p. 1145, doi. 10.1002/cncr.28561
    By:
    • Reckamp, Karen L.;
    • Giaccone, Giuseppe;
    • Camidge, D. Ross;
    • Gadgeel, Shirish M.;
    • Khuri, Fadlo R.;
    • Engelman, Jeff A.;
    • Koczywas, Marianna;
    • Rajan, Arun;
    • Campbell, Alicyn K.;
    • Gernhardt, Diana;
    • Ruiz‐Garcia, Ana;
    • Letrent, Stephen;
    • Liang, Jane;
    • Taylor, Ian;
    • O'Connell, Joseph P.;
    • Jänne, Pasi A.
    Publication type:
    Article
    46
    47
    48
    49
    50